South Korea · Delayed Price · Currency is KRW SK Biopharmaceuticals Statistics
Total Valuation
KRX:326030 has a market cap or net worth of KRW 6.21 trillion. The enterprise value is 5.95 trillion.
| Market Cap | 6.21T |
| Enterprise Value | 5.95T |
Important Dates
The next estimated earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:326030 has 78.31 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 78.31M |
| Shares Outstanding | 78.31M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 10.83% |
| Float | 39.02M |
Valuation Ratios
The trailing PE ratio is 17.81 and the forward PE ratio is 19.08. KRX:326030's PEG ratio is 0.96.
| PE Ratio | 17.81 |
| Forward PE | 19.08 |
| PS Ratio | 7.86 |
| PB Ratio | 6.66 |
| P/TBV Ratio | 7.08 |
| P/FCF Ratio | 39.11 |
| P/OCF Ratio | 37.19 |
| PEG Ratio | 0.96 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.65, with an EV/FCF ratio of 37.47.
| EV / Earnings | 17.06 |
| EV / Sales | 7.53 |
| EV / EBITDA | 23.65 |
| EV / EBIT | 25.29 |
| EV / FCF | 37.47 |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.49 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.31 |
| Interest Coverage | 41.53 |
Financial Efficiency
Return on equity (ROE) is 44.16% and return on invested capital (ROIC) is 43.34%.
| Return on Equity (ROE) | 44.16% |
| Return on Assets (ROA) | 14.43% |
| Return on Invested Capital (ROIC) | 43.34% |
| Return on Capital Employed (ROCE) | 26.58% |
| Weighted Average Cost of Capital (WACC) | 8.14% |
| Revenue Per Employee | 3.21B |
| Profits Per Employee | 1.42B |
| Employee Count | 246 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 0.45 |
Taxes
| Income Tax | -105.84B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.80% in the last 52 weeks. The beta is 0.70, so KRX:326030's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -23.80% |
| 50-Day Moving Average | 90,232.00 |
| 200-Day Moving Average | 107,828.50 |
| Relative Strength Index (RSI) | 34.41 |
| Average Volume (20 Days) | 176,816 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:326030 had revenue of KRW 790.25 billion and earned 348.81 billion in profits. Earnings per share was 4,452.45.
| Revenue | 790.25B |
| Gross Profit | 743.51B |
| Operating Income | 268.03B |
| Pretax Income | 230.53B |
| Net Income | 348.81B |
| EBITDA | 284.28B |
| EBIT | 268.03B |
| Earnings Per Share (EPS) | 4,452.45 |
Balance Sheet
The company has 310.86 billion in cash and 49.98 billion in debt, with a net cash position of 260.88 billion or 3,331.24 per share.
| Cash & Cash Equivalents | 310.86B |
| Total Debt | 49.98B |
| Net Cash | 260.88B |
| Net Cash Per Share | 3,331.24 |
| Equity (Book Value) | 932.05B |
| Book Value Per Share | 11,901.59 |
| Working Capital | 464.73B |
Cash Flow
In the last 12 months, operating cash flow was 166.97 billion and capital expenditures -8.19 billion, giving a free cash flow of 158.78 billion.
| Operating Cash Flow | 166.97B |
| Capital Expenditures | -8.19B |
| Depreciation & Amortization | 16.25B |
| Net Borrowing | -81.88B |
| Free Cash Flow | 158.78B |
| FCF Per Share | 2,027.49 |
Margins
Gross margin is 94.09%, with operating and profit margins of 33.92% and 44.14%.
| Gross Margin | 94.09% |
| Operating Margin | 33.92% |
| Pretax Margin | 29.17% |
| Profit Margin | 44.14% |
| EBITDA Margin | 35.97% |
| EBIT Margin | 33.92% |
| FCF Margin | 20.09% |
Dividends & Yields
KRX:326030 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.07% |
| Shareholder Yield | -0.07% |
| Earnings Yield | 5.62% |
| FCF Yield | 2.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KRX:326030 is 134,909.09, which is 80.12% higher than the current price. The consensus rating is "Buy".
| Price Target | 134,909.09 |
| Price Target Difference | 80.12% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 22.37% |
| EPS Growth Forecast (3Y) | 23.91% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KRX:326030 has an Altman Z-Score of 14.43 and a Piotroski F-Score of 6.
| Altman Z-Score | 14.43 |
| Piotroski F-Score | 6 |